Healthcare Stocks See Mixed Performance in Thursday's After-Market Session
ByAinvest
Thursday, Jul 17, 2025 7:26 pm ET1min read
BCLI--
Telomir Pharmaceuticals' stock increased by 52.1% to $1.84, reflecting strong market sentiment towards the company. Meanwhile, Brainstorm Cell Therapeutics' stock decreased by 49.6% to $0.59, indicating a significant drop in investor confidence. VYNE Therapeutics' shares rose by 6.77% to $1.26, following positive developments in its VYN202 program for moderate-to-severe plaque psoriasis. Nurix Therapeutics' stock moved upwards by 6.45% to $12.87, while Synlogic's stock increased by 6.02% to $1.76. Salarius Pharmaceuticals' stock also saw a gain of 5.33% to $0.63 [2].
Redhill Biopharma's stock fell by 8.68% to $2.21, Sonoma Pharmaceuticals' stock declined by 7.44% to $3.31, Plus Therapeutics' stock decreased by 6.58% to $0.36, Vivani Medical's stock fell by 5.67% to $1.5, and Verrica Pharmaceuticals' stock dropped by 5.29% to $0.81 [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TC0AI:0-australian-healthcare-stocks-gain-as-csl-advances-to-1-1-2-month-high/
[2] https://www.benzinga.com/insights/movers/25/07/46482121/12-health-care-stocks-moving-in-thursdays-after-market-session
[3] https://finance.yahoo.com/news/vyne-therapeutics-inc-vyne-gets-231802093.html
NRIX--
PSTV--
RDHL--
SLRX--
Healthcare stocks moved significantly in Thursday's after-market session. Telomir Pharmaceuticals' stock increased by 52.1% to $1.84, while Brainstorm Cell Therapeutics' stock decreased by 49.6% to $0.59. Other notable gainers include VYNE Therapeutics, Nurix Therapeutics, Synlogic, and Salarius Pharmaceuticals. Losers include Redhill Biopharma, Sonoma Pharmaceuticals, Plus Therapeutics, Vivani Medical, and Verrica Pharmaceuticals.
Healthcare stocks experienced significant movement in Thursday's after-market session. Telomir Pharmaceuticals' stock surged by 52.1% to $1.84, while Brainstorm Cell Therapeutics' stock declined by 49.6% to $0.59. Other notable gainers included VYNE Therapeutics, Nurix Therapeutics, Synlogic, and Salarius Pharmaceuticals. Conversely, Redhill Biopharma, Sonoma Pharmaceuticals, Plus Therapeutics, Vivani Medical, and Verrica Pharmaceuticals were among the losers [2].Telomir Pharmaceuticals' stock increased by 52.1% to $1.84, reflecting strong market sentiment towards the company. Meanwhile, Brainstorm Cell Therapeutics' stock decreased by 49.6% to $0.59, indicating a significant drop in investor confidence. VYNE Therapeutics' shares rose by 6.77% to $1.26, following positive developments in its VYN202 program for moderate-to-severe plaque psoriasis. Nurix Therapeutics' stock moved upwards by 6.45% to $12.87, while Synlogic's stock increased by 6.02% to $1.76. Salarius Pharmaceuticals' stock also saw a gain of 5.33% to $0.63 [2].
Redhill Biopharma's stock fell by 8.68% to $2.21, Sonoma Pharmaceuticals' stock declined by 7.44% to $3.31, Plus Therapeutics' stock decreased by 6.58% to $0.36, Vivani Medical's stock fell by 5.67% to $1.5, and Verrica Pharmaceuticals' stock dropped by 5.29% to $0.81 [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TC0AI:0-australian-healthcare-stocks-gain-as-csl-advances-to-1-1-2-month-high/
[2] https://www.benzinga.com/insights/movers/25/07/46482121/12-health-care-stocks-moving-in-thursdays-after-market-session
[3] https://finance.yahoo.com/news/vyne-therapeutics-inc-vyne-gets-231802093.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet